[1] |
Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer[J]. Oral Oncol, 2009, 45(4-5): 309-316.
doi: 10.1016/j.oraloncology.2008.06.002
pmid: 18804401
|
[2] |
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359-E386.
|
[3] |
Mbatchi LC, Gassiot M, Pourquier P, et al. Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer[J]. Cancer Chemother Pharmacol, 2017, 80(3): 653-659.
doi: 10.1007/s00280-017-3379-5
URL
|
[4] |
Wahlang B, Falkner KC, Cave MC, et al. Role of cytochrome P450 monooxygenase in carcinogen and chemotherapeutic drug metabolism[J]. Adv Pharmacol, 2015, 74: 1-33.
|
[5] |
Mitra R, Guo ZJ, Milani M, et al. CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducing nuclear translocation of phospho-Stat3 through biosynthesis of (±)-14, 15-epoxyeicosatrienoic acid (EET[J]. J Biol Chem, 2011, 286(20): 17543-17559.
doi: 10.1074/jbc.M110.198515
URL
|
[6] |
Fleming I. The cytochrome P450 pathway in angiogenesis and endothelial cell biology[J]. Cancer Metastasis Rev, 2011, 30(3-4): 541-555.
doi: 10.1007/s10555-011-9302-3
URL
|
[7] |
Jiang F, Chen L, Yang YC, et al. CYP3A5 functions as a tumor suppressor in hepatocellular carcinoma by regulating mTORC2/Akt signaling[J]. Cancer Res, 2015, 75(7): 1470-1481.
doi: 10.1158/0008-5472.CAN-14-1589
pmid: 25649767
|
[8] |
Wang HC, Chiang WF, Huang HH, et al. Promoter hypermethylation of the gene encoding heat shock protein B1 in oral squamous carcinoma cells[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2013, 115(3): 376-384.
doi: 10.1016/j.oooo.2012.12.011
URL
|
[9] |
王倩, 侯大为. 口腔鳞状细胞癌发病及转移机制研究进展[J]. 口腔医学研究, 2018, 34(11): 1164-1167.
doi: 10.13701/j.cnki.kqyxyj.2018.11.005
|
[10] |
de Vicente JC, Rodríguez-Santamarta T, Rosado P, et al. Survival after free flap reconstruction in patients with advanced oral squamous cell carcinoma[J]. J Oral Maxillofac Surg, 2012, 70(2): 453-459.
doi: 10.1016/j.joms.2011.02.020
URL
|
[11] |
Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy[J]. Mol Carcinog, 1995, 13(3): 129-134.
doi: 10.1002/mc.v13:3
URL
|
[12] |
Lamba JK, Lin YS, Schuetz EG, et al. Genetic contribution to variable human CYP3A-mediated metabolism[J]. Adv Drug Deliv Rev, 2002, 54(10): 1271-1294.
doi: 10.1016/S0169-409X(02)00066-2
URL
|
[13] |
Wojnowski L. Genetics of the variable expression of CYP3A in humans[J]. Ther Drug Monit, 2004, 26(2): 192-199.
pmid: 15228164
|
[14] |
Picard N, Rouguieg-Malki K, Kamar N, et al. CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients[J]. Transplantation, 2011, 91(6): 652-656.
doi: 10.1097/TP.0b013e31820ae4ac
pmid: 21389905
|
[15] |
Zayed BEM, Mehaney D. The effect of CYP3A5 polymorphism on cyclosporine plasma level in Egyptian renal transplant recipients[J]. Comp Clin Pathol, 2015, 24(4): 811-815.
doi: 10.1007/s00580-014-1987-6
URL
|
[16] |
Dhaini HR, Thomas DG, Giordano TJ, et al. Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma[J]. J Clin Oncol, 2003, 21(13): 2481-2485.
pmid: 12829666
|